OR WAIT null SECS
May 06, 2015
Alexion announces it will expand its rare disease pipeline with a definitive agreement to acquire Synageva.
Eleven of the leading US biosimilar developers have collaborated to form the Biosimilars Forum, a nonprofit organization formed to expand patient access to biosimilars.
April 30, 2015
Perrigo rejected Mylan’s second proposal for an acquisition valued at more than $34 billion, saying that the offer was too low to consider.
Takeda Pharmaceutical agrees to pay $2.4 billion to settle lawsuits from patients and family members who said the diabetes drug Actos caused bladder cancer.
April 29, 2015
In a seething letter, Mylan’s executive chairman announced the unanimous rejection of a $40-billion unsolicited acquisition offer from Teva.
After rejecting Teva’s unsolicited $40 billion purchase offer, Mylan has increased its own offer to purchase Perrigo from $29 billion to over $32 billion in cash in stocks.
April 28, 2015
FDA releases long-awaited guidance documents regarding the assessment of biosimilarity.
April 23, 2015
Originator product manufacturers will have to update and improve their processing platforms to stay competitive with the biosimilars coming to market.
Prequalified manufacturing suites could benefit from a new business model, say some industry executives.
April 22, 2015
INTERPHEX 2015 is under way and Pharmaceutical Technology and BioPharm International are in the middle of the action!